Can molecular insights guide treatment of AML evolved from MPNs?
Journal: 2021/December - Best Practice and Research in Clinical Haematology
Leukemic transformation of myeloproliferative neoplasms (MPNs) is associated with dismal outcomes. The genetic complexity of leukemic transformation of MPNs is being deciphered and will likely result in targeted therapy approaches. Ongoing trials are investigating the efficacy of emerging treatments for this high-risk patient population. This review has outlined recent progress in the understanding and treatment of leukemia arising from MPNs.
Keywords: AML; Acute myeloid leukemia; Allo-HSCT; Allogeneic hematopoietic stem cell transplantation; CR; Complete remission; JAK2V617F; MPNs; Myeloproliferative neoplasms; OS; Overall survival; STK11; Serine threonine kinase 11; TP53.
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.